Akero Therape Rg-AI
AKRO
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
08/30/2025 - 02:00:00
Bid
08/29/2025 - 21:59:59
Bid
Volume
Ask
08/29/2025 - 21:59:59
Ask
Volume
46.73
-0.21 ( -0.45% )
46.65
1,800
46.73
200
More information
Analysis by TheScreener
29.08.2025
Evaluation Slightly negative  
Interest Very weak  
Sensibility High  
Analysis date: 29.08.2025
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 12.08.2025.
Interest
  Very weak
One star since 12.08.2025.
Earnings Rev Trend
  Positive
 
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 12.08.2025 at a price of 48.03.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Negative
 
The dividend-adjusted forty day technical trend is negative since 29.07.2025.
4wk Rel Perf
  -3.00%
 
The four-week dividend-adjusted underperformance versus SP500 is 3.00%.
Sensibility
  High
The stock has been on the high-sensitivity level since 15.07.2025.
Bear Market Factor
  Low
On average, the stock has a tendency to minimize the drops in the index by -2.12%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 4.66%.
Mkt Cap in $bn
  3.74
With a market capitalization between $2 & $8bn, AKERO THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
  -1.09
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
  -9.33
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  -10.16%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
  9
Over the last seven weeks, an average of 9 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  49
For 1% of index variation, the stock varies on average by 0.49%.
Correlation
  0.07
Stock movements are totally independent of index variations.
Value at Risk
  30.84
The value at risk is estimated at USD 30.84. The risk is therefore 66.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  15.07.2025